BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Johnson & Johnson (JNJ)'s Zytiga Scores Big Win, Hurts Dendreon Corporation (DNDN), Helps Medivation, Inc. (MDVN)


3/8/2012 7:43:00 AM

Johnson & Johnson's(JNJ_) prostate cancer drug Zytiga prolonged the lives of patients with less advanced disease, according to results of a late-stage study announced Thursday. Zytiga, a pill, is now in line to treat the same prostate cancer patients targeted by Dendreon(DNDN_) with its Provenge immunotherapy. Dendreon shares fell $1.28 or 12% to $9.64 in Thursday's pre-market on fears that Zytiga competition may further erode already-underperforming Provenge sales. Meantime, Medivation(MDVN_) shares jumped $9.61 or 15% to $73.80 because its prostate cancer drug MDV3100 is a close cousin to Zytiga. Medivation is also conducting a late-stage study of MDV3100 in the same population of prostate cancer patients.

Read at The Street.com
Read at Wall Street Journal
Read at Reuters

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->